Almet Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.60 M
as on 08-11-2024
- Paid Up Capital ₹ 1.60 M
as on 08-11-2024
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
as on 08-11-2024
- Satisfied Charges ₹ 4.90 M
as on 08-11-2024
- Revenue 115.77%
(FY 2022)
- Profit 656.29%
(FY 2022)
- Ebitda 1896.06%
(FY 2022)
- Net Worth 7.14%
(FY 2022)
- Total Assets 33.27%
(FY 2022)
About Almet Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.60 M and a paid-up capital of Rs 1.60 M.
The company currently has active open charges totaling ₹9.00 M. The company has closed loans amounting to ₹4.90 M, as per Ministry of Corporate Affairs (MCA) records.
Vaibhav Parekh, Rajesh Bhardwaj, and Abhishek Bhansali serve as directors at the Company.
- CIN/LLPIN
U74999GJ2020PTC113417
- Company No.
113417
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Almet Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaibhav Parekh  | Director | 15-Apr-2020 | Current |
| Rajesh Bhardwaj | Director | 02-Sep-2020 | Current |
| Abhishek Bhansali | Director | 07-Jun-2021 | Current |
Financial Performance and Corporate Structure Insights of Almet Lifesciences.
Almet Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 115.77% increase. The company also saw a substantial improvement in profitability, with a 656.29% increase in profit. The company's net worth moved up by a moderate rise of 7.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Almet Lifesciences?
Unlock access to Almet Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 Jul 2023 | ₹9.00 M | Open |
Others Creation Date: 06 Aug 2022 | ₹4.90 M | Satisfied |
How Many Employees Work at Almet Lifesciences?
Almet Lifesciences has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Almet Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Almet Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
